Palumbo Wealth Management LLC Invests $437,000 in uniQure (NASDAQ:QURE)

Palumbo Wealth Management LLC purchased a new position in shares of uniQure (NASDAQ:QURE) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,749 shares of the biotechnology company’s stock, valued at approximately $437,000. Palumbo Wealth Management LLC owned about 0.05% of uniQure as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new position in shares of uniQure during the fourth quarter worth approximately $88,000. RTW Investments LP acquired a new position in shares of uniQure during the third quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc acquired a new position in shares of uniQure in the third quarter valued at $53,000. Finally, Quarry LP acquired a new position in shares of uniQure in the third quarter valued at $58,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $14.18 on Friday. The business’s fifty day moving average price is $15.54 and its two-hundred day moving average price is $9.44. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

Analysts Set New Price Targets

A number of research analysts recently commented on QURE shares. StockNews.com upgraded uniQure to a “sell” rating in a research note on Wednesday, February 5th. HC Wainwright upped their target price on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Leerink Partners upped their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.00.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.74% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.